Salvia przewalskii extract of total phenolic acids inhibit TLR4 signaling activation in podocyte injury induced by puromycin aminonucleoside in vitro

Figures & data

Table 1. The primer sequences.

Primer	Primer sequences		Annealing temperature (°C)
TLR4	Forward	5′-CAAGAACATAGATCTGAGCTTCAACCC	60
	Reverse	5′-GCTGTCCAATAGGGAAGCTTTCTAGAG
MyD88	Forward	5′-AAGAAAGTGAGTCTCCCCTC	55
	Reverse	5′-TCCCATGAAACCTCTAACAC
NF-κB	Forward	5′-GCTCGGCTGAATGAATCTACC	60
	Reverse	5′-GTCTCCACGTATTTCCGCAACT
β-Actin	Forward	5′-GGGAAATCGTGCGTGACATTAAG	60
	Reverse	5′-TGTGTTGGCGTACAGGTCTTTG

Figure 1. Tacrolimus, SPE, SalB and RA reversed PAN-induced podocyte actin cytoskeletal injury (× 1000). (A) Untreated normal control; (B) PAN; (C) SPE, 158 g/mL; (D) SPE, 316 g/mL; (E) RA, 25 g/mL; (F) RA, 50 g/mL; (G) SalB, 8.5 g/mL; (H) SalB, 17 g/mL; (I) SalB and RA, 8.5 + 25 g/mL combined; (J) SalB and RA, 17 + 50 g/mL combined; (K) positive drug control.

Figure 2. The effects of SPE and monomer on TLR4 mRNA levels in PAN-treated podocytes. NC, untreated control; PAN, model; SPE-L, 158 g/mL; SPE-H, 316 g/mL; SB-L, 8.5 g/mL; SB-H, 17 g/mL; RA-L, 25 g/mL; RA-H, 50 g/mL; H-L, SalB + RA (8.5 + 25 g/mL) combined; H-H, SalB + RA (17 + 50 g/mL) combined; Tac. positive control. Note: *p < .05 vs. NC; +p < .05 vs. PAN; #p > .05 vs. NC

Figure 3. The effects of SPE and monomers on MyD88 mRNA levels in PAN-treated podocytes. NC, untreated control; PAN, model; SPE-L, 158 g/mL; SPE-H, 316 g/mL; SB-L, 8.5 g/mL; SB-H, 17 g/mL; RA-L, 25 g/mL; RA-H, 50 g/mL; H-L, SalB + RA (8.5 + 25 g/mL) combined; H-H, SalB + RA (17 + 50 g/mL) combined; Tac. positive control. Note: *p < .05 vs. NC; +p < .05 vs. PAN; #p > .05 vs. NC.

Figure 4. The effects of SPE and monomers on NF-kB mRNA level in PAN-treated podocytes. NC, untreated control; PAN, model; SPE-L, 158 g/mL; SPE-H, 316 g/mL; SB-L, 8.5 g/mL; SB-H, 17 g/mL; RA-L, 25 g/mL; RA-H, 50 g/mL; H-L, SalB + RA (8.5 + 25 g/mL) combined; H-H, SalB + RA (17 + 50 g/mL) combined; Tac. positive control. Note: *p < .05 vs. NC; +p < .05 vs. PAN; #p > .05 vs. NC

Figure 5. The effects of SPE and its monomers on the expression of TLR4 in PAN-treated podocytes. NC, untreated normal control; PAN, injury model; SPE-L, 158 g/mL; SPE-H, 316 g/mL; SB-L, 8.5 g/mL; SB-H, 17 g/mL; RA-L, 25 g/mL; RA-H, 50 g/mL; H-L, SalB + RA (8.5 + 25 g/mL) combined; H-H, SalB + RA (17 + 50 g/mL) combined; Tac. positive control. Note: *p < .05 vs. NC; +p < .05 vs. PAN; #p > .05 vs. NC

Figure 6. The effects of SPE and its monomers on the level of pp65 in PAN-treated podocytes. NC, untreated control; PAN, model; SPE-L, 158 g/mL; SPE-H, 316 g/mL; SB-L, 8.5 g/mL; SB-H, 17 g/mL group; RA-L, 25 g/mL; RA-H, 50 g/mL; H-L, SalB + RA (8.5 + 25 g/mL) combined; H-H, SalB + RA (17 + 50 g/mL) combined; Tac. positive control. Note: *p < .05 vs. NC; +p < .05 vs. PAN; #p > .05 vs. NC

Figure 7. The effects of SPE and its monomers on the expression of MyD88 in PAN-treated podocytes. NC, untreated normal control; PAN, injury model; SPE-L, 158 g/mL; SPE-H, 316 g/mL; SB-L, 8.5 g/mL; SB-H, 17 g/mL; RA-L, 25 g/mL; RA-H, 50 g/mL; H-L, 8.5 + 25 g/mL combined; H-H, SalB + RA (17 + 50 g/mL) combined; Tac. positive control. Note: *p < .05 vs. NC; +p < .05 vs. PAN; #p > .05 vs. NC